Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment

Biomedicine and Pharmacotherapy

Volumn 67, Issue 8, 2013, Pages 807-817

  Nicolini, Andrea ^a   Ferrari, Paola ^a   Masoni, Maria Chiara ^b   Fini, Milena ^c   Pagani, Stefania ^c   Giampietro, Ottavio ^b   Carpi, Angelo ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Anorexia; Cachexia; Cancer; Malnutrition; Treatment

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; INTERFERON; IRINOTECAN; LAPATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; SEROTONIN; TAXANE DERIVATIVE; THYMIDINE KINASE INHIBITOR; VINCRISTINE;

ABDOMINAL DISCOMFORT; ANOREXIA; ARCUATE NUCLEUS; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARBOHYDRATE METABOLISM; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DUMPING SYNDROME; DYSGEUSIA; DYSPHAGIA; ENTERIC FEEDING; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GASTRECTOMY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL OBSTRUCTION; HEAD AND NECK CANCER; HUMAN; LARYNGECTOMY; LEUKEMIA; LIPID METABOLISM; LOSS OF APPETITE; LYMPHOMA; MALABSORPTION; MALNUTRITION; MEDIASTINUM TUMOR; METABOLIC DISORDER; MUCOSA INFLAMMATION; MUCOSAL DISEASE; ODYNOPHAGIA; PANCREATICODUODENECTOMY; PARENTERAL NUTRITION; PATHOGENESIS; PHARYNGOLARYNGECTOMY; PRIORITY JOURNAL; PROTEIN METABOLISM; RADIATION ENTEROPATHY; RADIATION INDUCED EMESIS; REVIEW; SATIETY; STOMACH CANCER; WEIGHT REDUCTION;

ANOREXIA; CACHEXIA; CANCER; MALNUTRITION; TREATMENT;

ANOREXIA; CACHEXIA; CARBOHYDRATE METABOLISM; ENERGY METABOLISM; HUMANS; MALNUTRITION; NEOPLASMS; PROTEINS;

EID: 84887618644     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.08.005     Document Type: Review

References (156)

1. Senesse P., Assenat E., Schneider S., Chargari C., Magné N., Azria D., et al. Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit?. Cancer Treat Rev 2008, 34(6):568-575.
2. Soeters P.B., Schols A.M. Advances in understanding and assessing malnutrition. Curr Opin Clin Nutr Metab Care 2009, 12(5):487494.
3. Weimann A., Braga M., Harsanyi L., Laviano A., Ljungqvist O., Soeters P., et al. ESPEN Guidelines on enteral nutrition: surgery including organ transplantation. Clin Nutr 2006, 25(2):224-244.
4. Argilés J.M., Olivan M., Busquets S., López-Soriano F.J. Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res 2010, 2:27-38.
5. Murphy K.T., Lynch G.S. Editorial update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2012, 17(1):5-9.
6. Kumar N.B., Kazi A., Smith T., Crocker T., Yu D., Reich R.R., et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010, 11(3-4):107-117.
7. Arends J., Bodoky G., Bozzetti F., Fearon K., Muscaritoli M., Selga, et al. ESPEN Guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006, 25(2):245-259.
8. Kelsen D.P., Ginsberg R., Pajak T.F., Sheahan D.G., Gunderson L., Mortimer J., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339(27):1979-1984.
9. Sánchez-Bueno F., Garcia-Marcilla J.A., Perez-Flores D., Pérez-Abad J.M., Vicente R., Aranda F., et al. Prognostic factors in a series of 297 patients with gastric adenocarcinoma undergoing surgical resection. Br J Surg 1998, 85(2):255-260.
10. Alves A., Panis Y., Mathieu P., Mantion G., Kwiatkowski F., Slim K., et al. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg 2005, 140(3):278-283.
11. Bachmann J., Heiligensetzer M., Krakowski-Roosen H., Büchler M.W., Friess H., Martignoni M.E. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008, 12(7):1193-1201.
12. Von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005, 9(Suppl. 2):S35-S38.
13. Chasen M.R., Bhargava R. A descriptive review of the factors contributing to nutritional compromise in patients with head and neck cancer. Support Care Cancer 2009, 17(11):1345-1351.
14. Quon H. Cancer of the head and neck. Clinical oncology 2008, 1177-1228. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 72]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
15. Sovak A.M., et al. Tumors of the pleura and mediastinum. Clinical oncology 2008, 1367-1398. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 77]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
16. Kleinberg L.R., et al. Cancer of the esophagus. Clinical oncology 2008, 1399-1429. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 78]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
17. Gunderson L.L., et al. Cancer of the stomach. Clinical oncology 2008, 1431-1464. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 79]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
18. Fichera A., et al. Cancer of the small bowel. Clinical oncology 2008, 1465-1476. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 80]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
19. Compton C., et al. Colon cancer. Clinical oncology 2008, 1477-1534. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 81]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
20. Fazal S., Saif M.W. Supportive and palliative care of pancreatic cancer. JOP 2007, 8(2):240-253.
21. Oberg K., Akerström G., Rindi G., Jelic S. Neuroendocrine gastroenteropancreatic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v223-v227. Guidelines Working Group E.S.M.O.
22. Grahme-Smith D. The carcinoid sindrome 1972, Heinemann, London.
23. Isenberg J.I., Walsh J.H., Grossman M.I. Zollinger-Ellison syndrome. Gastroenterology 1973, 65(1):140-165.
24. Bozzetti F. Cachessia neoplastica. Medicina Oncologica 2007, 1829-1844. Elsevier Masson, Milan (Italy), [Chap 66]. 8th Edition. G. Bonadonna, G. Robustelli della Cuna, P. Valagussa (Eds.).
25. Pauloski B.R., Logemann J.A., Rademaker A.W., McConnel F.M., Stein D., Beery Q., et al. Speech and swallowing function after oral and oropharyngeal resections: one-year follow-up. Head Neck 1994, 16(4):313-322.
26. Zuydam A.C., Lowe D., Brown J.S., Vaughan E.D., Rogers S.N. Predictors of speech and swallowing function following primary surgery for oral and oropharyngeal cancer. Clin Otolaryngol 2005, 30(5):428-437.
27. Ward E.C., Bishop B., Frisby J., Stevens M. Swallowing outcomes following laryngectomy and pharyngolaryngectomy. Arch Otolaryngol Head Neck Surg 2002, 128(2):181-186.
28. Abendstein H., Nordgren M., Boysen M., Jannert M., Silander E., Ahlner-Elmqvist M., et al. Quality of life and head and neck cancer: a 5-year prospective study. Laryngoscope 2005, 115(12):2183-2192.
29. NCCN Clinical Practice Guidelines in Oncology, Palliative Care, version I.2012. http://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf.
30. Haverkort E.B., Binnekade J.M., Busch O.R., van Berge Henegouwen M.I., de Haan R.J., Gouma D.J. Presence and persistence of nutrition-related symptoms during the first year following esophagectomy with gastric tube reconstruction in clinically disease-free patients. World J Surg 2010, 34(12):2844-2852.
31. Ryan A.M., Healy L.A., Power D.G., Rowley S.P., Reynolds J.V. Short-term nutritional implications of total gastrectomy for malignancy, and the impact of parenteral nutritional support. Clin Nutr 2007, 26(6):718-727.
32. Ryu S.W., Kim I.H. Comparison of different nutritional assessments in detecting malnutrition among gastric cancer patients. World J Gastroenterol 2010, 16:3310-3317.
33. Friess H., Böhm J., Müller M.W., Glasbrenner B., Riepl R.L., Malfertheiner P., et al. Maldigestion after total gastrectomy is associated with pancreatic insufficiency. Am J Gastroenterol 1996, 91(2):341-347.
34. Morrison M. Post-pancreatic resection: general overview and unique complications. Dimens Crit Care Nurs 2010, 29(4):157-162.
35. Kahl S., Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol 2004, 18(5):947-955.
36. Jang J.Y., Kim S.W., Park S.J., Park Y.H. Comparison of the functional outcome after pylorus-preserving pancreatoduodenectomy: pancreatogastrostomy and pancreatojejunostomy. World J Surg 2002, 26(3):366-371.
37. Ghaneh P., Neoptolemos J.P. Exocrine pancreatic function following pancreatectomy. Ann N Y Acad Sci 1999, 880:308-318.
38. Domínguez-Muñoz J.E. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep 2007, 9(2):116-122.
39. Smith G.P. Controls of food intake. Modern Nutrition in health and disease 2005, Lippincott Williams and Wilkins, Philadelphia (PA). M.E. Shils, M. Shike, A.C. Ross, B. Caballero, R.J. Cousins (Eds.).
40. Ferrari S., Palmerini E., Alberghini M., Staals E., Mercuri M., Barbieri E., et al. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with non-metastatic Ewing sarcoma. Final results of a monoinstitutional study. Tumori 2010, 96(2):213-218.
41. Hainsworth J.D., et al. Nausea and vomiting. Clinical oncology 2008, 599-608. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 39]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
42. Maranzano E., De Angelis V., Pergolizzi S., Lupattelli M., Frata P., Spagnesi S., et al. Italian Group for Antiemetic Research in Radiotherapy - IGARR. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 2010, 94(1):36-41.
43. NCCN Clinical Practice Guidelines in Oncology, Antiemesis, version I.2012. http://www.nccn.org/professionals/physician_gls/pdf/.
44. Raber-Durlacher J.E., Elad S., Barasch A. Oral mucositis. Oral Oncol 2010, 46:452-456.
45. Sideras K., Loprinzi C.L., Foote R.L. Oral complications. Clinical oncology 2008, 609-623. Churchill Livingstone-Elsevier, Philadelphia (PA), [Chap 40]. 4th ed. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
46. Foote R.L., Loprinzi C.L., Frank A.R., O'Fallon J.R., Gulavita S., Tewfik H.H., et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 1994, 12(12):2630-2633.
47. Wijers O.B., Levendag P.C., Harms E.R., Gan-Teng A.M., Schmitz P.I., Hendriks W.D., et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 2001, 50(2):343-352.
48. Ehrnrooth E., Grau C., Zachariae R., Andersen J. Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncol 2001, 40(6):745-750.
49. Janjan N.A., Weissman D.E., Pahule A. Improved pain management with daily nursing intervention during radiation therapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 1992, 23(3):647-652.
50. Caglar H.B., Othus M., Allen A.M. Esophagus in field: a new predictor for esophagitis. Radiother Oncol 2010, 97:48-53.
51. Mariani G., Lozza L. Danni iatrogenici. Medicina Oncologica 2007, 1753-1794. Elsevier Masson, Milan (Italy), [Chap 63]. 8th Edition. G. Bonadonna, G. Robustelli della Cuna, P. Valagussa (Eds.).
52. Shoemaker L.K., Estfan B., Induru R., Walsh T.D. Symptom management: an important part of cancer care. Cleve Clin J Med 2011, 78(1):25-34.
53. Senft M., Fietkau R., Iro H., Sailer D., Sauer R. The influence of supportive nutritional therapy via percutaneous endoscopically guided gastrostomy on the quality of life of cancer patients. Support Care Cancer 1993, 1(5):272-275.
54. Chua K.S., Reddy S.K., Lee M.C., Patt R.B. Pain and loss of function in head and neck cancer survivors. J Pain Symptom Manage 1999, 18(3):193-202.
55. Bhattacharyya N. Factors predicting survival for cancer of the ethmoid sinus. Am J Rhinol 2002, 16(5):281-286.
56. Ukleja A. Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract 2005, 20:517-525.
57. Di Fiore F., Van Cutsem E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol 2009, 23(1):113-124.
58. Herrstedt J., Aapro M.S., Roila F., Kataja V.V. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2005, 16(Suppl. 1):i77-i79.
59. Jordan K., Kasper C., Schmoll H.J. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005, 41(2):199-205.
60. Hesketh P.J., Grunberg S.M., Gralla R.J., Warr D.G., Roila F., de Wit R., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003, 21(22):4112-4119.
61. de Wit R., Herrstedt J., Rapoport B., Carides A.D., Carides G., Elmer M., et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003, 21(22):4105-4111.
62. Zaglama N.E., Rosenblum S.L., Sartiano G.P., Brady M., Gonzalez M.F., Valdivieso J.G. Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 1986, 43(1):27-32.
63. Italian group for antiemetic research Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004, 22(4):725-729.
64. Peterson D.E. New strategies for management of oral mucositis in cancer patients. J Support Oncol 2006, 4(2 Suppl. 1):9-13.
65. Jones J.A., Avritscher E.B., Cooksley C.D., Michelet M., Bekele B.N., Elting L.S. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006, 14(6):505515.
66. Keefe D.M., Schubert M.M., Elting L.S., Sonis S.T., Epstein J.B., Raber-Durlacher J.E., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007 Mar 1, 109(5):820-831.
67. Worthington H.V., Clarkson J.E., Bryan G., Furness S., Glenny A.M., Littlewood A., et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011, [CD000978].
68. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001, 27(Suppl. 2):S3-S11.
69. Katranci; N., Ovayolu N., Ovayolu O., Sevinc A. Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy-a randomized controlled trial. Eur J Oncol Nurs 2012, 16(4):339-344.
70. Rubenstein E.B., Peterson D.E., Schubert M., Keefe D., McGuire D., Epstein J., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004, 100(9 Suppl.):2026-2046.
71. Worthington H.V., Clarkson J.E., Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2006, (2). [CD000978. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD000978].
72. Baydar M., Dikilitas M., Sevinc A., Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc 2005, 97(8):1161-1164.
73. Savarese D.M., Savy G., Vahdat L., Wischmeyer P.E., Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003, 29(6):501-513.
74. Rosen L.S., Abdi E., Davis I.D., Gutheil J., Schnell F.M., Zalcberg J., et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006, 24(33):5194-5200.
75. NCI Guidelines on Oral Complications of Chemotherapy and Head/Neck Radiation, 2011. http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional.
76. Benson A.B, Ajani J.A., Catalano R.B., Engelking C., Kornblau S.M., Martenson J.A, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004, 22(14):2918-2926.
77. Cherny N.I. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage 2008, 36(4):413-423.
78. NCI Supportive and Palliative Care, Gastrointestinal Complications 2011. http://www.cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional/.
79. Richardson G., Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007, 13(4):181-198.
80. Schneeman B.O. Carbohydrates: significance for energy balance and gastrointestinal function. J Nutr 1994, 124(9 Suppl.):1747S-1753S.
81. NCI Supportive and Palliative Care, Nutrition 2011 http://www.cancer.gov/cancertopics/pdq/supportivecare/nutrition/HealthProfessional/.
82. Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance?. Gut 2005, 54(8):1051-1054.
83. Theis V.S., Sripadam R., Ramani V., Lal S. Chronic radiation enteritis. Clin Oncol (R Coll Radiol) 2010, 22(1):70-83.
84. Galland R.B., Spencer J. The natural history of clinically established radiation enteritis. Lancet 1985, 1(8440):1257-1258.
85. Andreyev H.J. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol) 2007, 19(10):790-799.
86. Miller A.R., Martenson J.A., Nelson H., Schleck C.D., Ilstrup D.M., Gunderson L.L., et al. The incidence and clinical consequences of treatment-related bowel injury. Int J Radiat Oncol Biol Phys 1999, 43(4):817-825.
87. Regimbeau J.M., Panis Y., Gouzi J.L., Fagniez P.L. Operative and long term results after surgery for chronic radiation enteritis. Am J Surg 2001, 182(3):237-242. French university association for surgical research.
88. Vantini I., Benini L., Bonfante F., Talamini G., Sembenini C., Chiarioni G., et al. Survival rate and prognostic factors in patients with intestinal failure. Dig Liver Dis 2004, 36(1):46-55.
89. Wickham R.S., Rehwaldt M., Kefer C., Shott S., Abbas K., Glynn-Tucker E., et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 1999, 26(4):697-706.
90. Bartoshuk L.M. Chemosensory alterations and cancer therapies. NCI Monogr 1990, 9:179-184.
91. Zabernigg A., Gamper E.M., Giesinger J.M., Rumpold G., Kemmler G., Gattringer K., et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect?. Oncologist 2010, 15(8):913-920.
92. Argiles J.M. Cancer-associated malnutrition. Eur J Oncol Nurs 2005, 9(Suppl. 2):S39-S50.
93. Barber M.D., Ross J.A., Fearon K.C. Cancer cachexia. Surg Oncol 1999, 8:133-141.
94. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005, 8:571-578.
95. Chaudhri O.B., Field B.C.T., Bloom S.R. From gut to mind-hormonal satiety signals and anorexia nervosa. J Clin Endocrinol Metab 2006, 91(3):797-798.
96. Rolls E.T. Taste, olfactory, and food texture processing in the brain, and the control of food intake. Physiol Behav 2005, 85(1):45-56.
97. Frasnelli J., Van Ruth S., Kriukova I., Hummel T. Intranasal concentrations of orally administered flavors. Chem Senses 2005, 30(7):575-582.
98. Rolls E.T., Sienkiewicz Z.J., Yaxleiy S. Hunger modulates the responses to gustatory stimuli of single neurons in the caudolateral orbitofrontal cortex of the macaque monkey. Eur J Neurosci 1989, 1:53-60.
99. Rolls E.T. Emotion explained 2005, Oxford University Press, Oxford.
100. Rolls E.T. Smell, taste, texture, and temperature multimodal representations in the brain, and their relevance to the control of appetite. Nutr 2004, 62:S193-S204.
101. Rolls E.T. The functions of the orbitofrontal cortex. Brain Cogn 2004, 55(1):11-29.
102. Verhagen J.V., Kadohisa M., Rolls E.T. The primate insular/opercular taste cortex: neuronal representations of the viscosity, fat texture, grittiness and taste of foods in the mouth. J Neurophysiol 2004, 92(3):1685-1699.
103. Kadoshisa M., Rolls E.T., Verhagen J.V. The primate amygdala: neuronal representations of the viscosity, fat texture, grittiness, and taste of foods in the mouth. Neuroscience 2005, 132:33-48.
104. Kadoshisa M., Rolls E.T., Verhagen J.V. Neural representations of stimuli in the mouth: the primate insular cortex, orbitofrontal cortex and amygdala. Chem Senses 2005, 30(5):401-419.
105. Adam T.C.M., Jocken J., Westerterp-Plantenga M.S. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 2005, 13:710-716.
106. Naslund E., King N., Mansten S., Adner N., Holst J.J., Gutniak M., et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004, 91:439-446.
107. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004, 145(6):2687-2695.
108. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005, 54(8):2390-2395.
109. Berthoud H.R. Neural control of appetite: cross-talk between homeostatic and non homeostatic systems. Appetite 2004, 43(3):315-317.
110. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. Trends Neurosci 1999, 22:62-67.
111. Williams G., Cai X.J., Elliott J.C., Harrold J.A. Anabolic neuropeptides. Physiol Behav 2004, 81:211-222.
112. Gropp E., Shanabrough M., Borok E., Xu A.W., Janoschek R., Buch T., et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci 2005, 8(10):1289-1291.
113. Ellacott K.L., Cone R.D. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res 2004, 59:395-408.
114. Feletou M., Levens N.R. Neuropeptide Y2 receptors as drug targets for the central regulation of body weight. Curr Opin Investig Drugs 2005, 6(10):1002-1011.
115. Chen H.Y., Trumbauer M.E., Chen A.S., Weingarth D.T., Adams J.R., Frazier E.G., et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004, 145:2607-2612.
116. Banks W.A. Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier. Nutrition 2001, 17(5):434-437.
117. Plata-Salamán C.R. Cytokines and anorexia: a brief overview. Semin Oncol 1998, 25(1 Suppl. 1):64-72.
118. Tisdale M.J. Mechanisms of cancer cachexia. Physiol Rev 2009, 89(2):381-410.
119. Gelin J., Moldawer L.L., Lonnroth C., Sherry B., Chizzonite R., Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991, 51:415-421.
120. Inui A., Neuropeptide Y. A key molecule in anorexia and cachexia in wasting disorders. Mol Med Today 1999, 5:79-85.
121. Johnen H., Lin S., Kuffner T., Brown D.A., Tsai V.W., Bauskin A.R., et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007, 13(11):1333-1340.
122. Machado A.P., Costa Rosa L.F., Seelaender M.C. Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res 2004, 318:503-514.
123. Laviano A., Meguid M.M., Inui A., Muscaritoli M., Rossi-Fanelli F. Therapy insight: cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat Clin Pract Oncol 2005, 2:158-165.
124. Marks D.L., Ling N., Cone R.D. Role of the central melanocortin system in cachexia. Cancer Res 2001, 61:1432-1438.
125. Lechan R.M., Tatro J.B. Hypothalamic melanocortin signaling in cachexia. Endocrinology 2001, 142:3288-3291.
126. Sonti G., Ilyin S.E., Neuropeptide Plata-Salaman C.R. Y blocks and reverses interleukin-1β-induced anorexia in rats. Peptides 1996, 17:517-520.
127. Sonti G., Ilyin S.E., Plata-Salaman C.R. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996, 270:1349-1402.
128. Plata-Salaman C.R., Ilyin S.E., Gayle D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol 1998, 275:566-573.
129. Moldawer L.L., Rogy M.A., Lowry S.F. The role of cytokines in cancer cachexia. JPEN J Parenter Enteral Nutr 1992, 16:43-49.
130. Kaye W.H., Frank G.K., Bailer U.F., Henry S.E., Meltzer C.C., Price J.C., et al. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiol Behav 2005, 85(1):73-81.
131. Sato T., Laviano A., Meguid M.M., Chen C., Rossi Fanelli F., Hatakeyama K. Involvement of plasma leptin, insulin and free tryptophan in cytokine-induced anorexia. Clin Nutr 2003, 22:139-146.
132. Yang Z.J., Blaha V., Meguid M.M., Laviano A., Oler A., Zadak Z. Interleukin-1alpha injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and release of dopamine and serotonin. Pharmacol Biochem Behav 1999, 62:61-65.
133. Tisdale M.J. Pathogenesis of cancer cachexia. J Support Oncol 2003, 1(3):159-168.
134. MacDonald N., Easson A.M., Mazurak V.C., Dunn G.P., Baracos V.E. Understanding and managing cancer cachexia. J Am Coll Surg 2003, 197:143-161.
135. Tayek J.A. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992, 11:445-446.
136. Tisdale M.J. Cancer anorexia and cachexia. Nutrition 2001, 17:438-442.
137. Tisdale M.J. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000, 16:1013-1014.
138. Agustsson T., Rydén M., Hoffstedt J., van Harmelen V., Dicker A., Laurencikiene J., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007, 67(11):5531-5537.
139. Baracos V.E. Regulation of skeletal-muscleprotein turnover in cancer-associated cachexia. Nutrition 2000, 16:1015-1018.
140. Nixon D.W., Heymsfield S.B., Cohen A.E., Kunter M.H., Ansley J., Lawson D.H., et al. Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 1980, 68:683-690.
141. Todorov P., Cariuk P., McDevitt T., Coles B., Fearon K., Tisdale M. Characterization of a cancer cachectic factor. Nature 1996, 379:739-742.
142. Lorite M.J., Thompson M.G., Drake J.L., Carling G., Tisdale M.J. Mechanisms of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 1998, 78:850-856.
143. Hasselgren P.-O., Wray C., Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Com 2002, 290(1):1-10.
144. Genth-Zotz S., Bolger A.P., Kalra P.R., von Haehling S., Doehner W., Coats A.J.S., et al. Heatshock protein 70 in patients with chronic heart failure: relation to disease severity and survival. Int J Cardiol 2004, 96:397-401.
145. Luo G., Sun X., Hungness E., Hasselgren P.O. Heat shock protects L6 myotubes from catabolic effects of dexamethasone and prevents downregulation of NF-kB. Am J Physiol Regulatory Integrative Comp Physiol 2001, 281:R1194-R1200.
146. Tanaka Y., Eda H., Fujimoto K., Tanaka T., Ishikawa T., Ishitsuka H. Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 1990, 50(15):4528-4532.
147. Tohgo A., Kumazawa E., Akahane K., Asakawa A., Inui A. Anticancer drugs that induce cancer-associated cachectic syndromes. Expert Rev Anticancer Ther 2002, 2(1):121-129.
148. Fujimoto-Ouchi K., Onuma E., Shirane M., Mori K., Tanaka Y. Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother Pharmacol 2007, 59(6):807-815.
149. Mantovani G., Madeddu C. Cancer cachexia: medical management. Support Care Cancer 2010, 18:1-9.
150. Argilés J.M., López-Soriano F.J., Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008, 13:73-78.
151. White J.V., Guenter P., Jensen G., Malone A., Schofield M. Consensus statement: academy of nutrition and dietetics and american society for parenteral and enteral nutrition: characteristics recommended for the identification and documentation of adult malnutrition. J Parenter Enteral Nutr 2012, 36:275-283. The Academy Malnutrition Work Group, the ASPEN Malnutrition Task Force, and the ASPEN Board of Directors.
152. Piccoli A., Brunani A., Savia G., Pillon L., Favaro E., Berselli M.E., et al. Discriminating between body fat and fluid changes in the obese adult using bioimpedance vector analysis. Int J Obesity 1998, 22:97-104.
153. Rossi Fanelli F., Cascino A., Muscaritoli M. Abnormal substrate metabolism and nutritional strategies in cancer management. J Parenter Enteral Nutr 1991, 15:680.
154. Mueller C., Compher C., Ellen D.M. and the American Society for Parenteral and Enteral Nutrition (ASPEN) Board of Directors. J Parenter Enteral Nutr 2011, 35:16-24.
155. Schattner M. Enteral nutritional support of the patient with cancer: route and role. J Clin Gastroenterol 2003, 36:297-302.
156. Joque L., Jatoi A. Total parenteral nutrition in cancer patients: why and when. Nutr Clin Care 2005, 8:89-92.